Get started
Work

A Randomized Control Trial of Ravulizumab for Treatment of Patients With COVID-19 Infection and Kidney Injury

Year: 2022
Type: article
Abstract: Patients affected by severe COVID-19 infection often develop end-organ damage that manifests as acute kidney injury (AKI).1,2 It has been reported that greater than 20% of such patients are diagnosed with AKI, but the long term impact on future prevalence of chronic kidney disease has yet to be rigorously quantitated.3 There is substantial evidence that primary events of AKI in this circumstance occur on the luminal surface of the endothelial cell in the microvasculature of the kidney,4-7 including histopathological descriptions of kidney-specific endothelitis and glomerular fibrin thrombi.
DOI: 10.1016/j.ekir.2022.09.003
Authors: Aliza A. Memon, Hasban Ahmed, Yi Li, Janewit Wongboonsin, Joshua Hundert, Stefanie Benoit, Advika Chaudhari, Jawad Sher, Pratima Ghimire, Rebecca Hopkins, Jay Patel, Melinda Stegman, Kenneth Lim, Jamil Azzi, Andrew M. Siedlecki
Institutions: Saint Louis University, Brigham and Women's Hospital, Harvard University, Cincinnati Children's Hospital Medical Center, Northeastern University, Indiana University School of Medicine, Salem Hospital
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,625
OpenAlex ID: W4295292726
FWCI: 1.111
Cites: 9
Cited by: 8
Related to: 10